Open Access
| Issue |
BIO Web Conf.
Volume 174, 2025
2025 7th International Conference on Biotechnology and Biomedicine (ICBB 2025)
|
|
|---|---|---|
| Article Number | 02021 | |
| Number of page(s) | 7 | |
| Section | Innovations in Therapeutics and Disease Mechanisms | |
| DOI | https://doi.org/10.1051/bioconf/202517402021 | |
| Published online | 12 May 2025 | |
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 74(3), 229–263. [CrossRef] [PubMed] [Google Scholar]
- Yin, L., Duan, J. J., Bian, X. W., & Yu, S. C. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. Breast cancer research: BCR, 22(1), 61. [CrossRef] [Google Scholar]
- Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022). Recent advances in therapeutic strategies for triple-negative breast cancer. Journal of hematology & oncology, 15(1), 121. [CrossRef] [PubMed] [Google Scholar]
- Kanai Y. (2022). Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacology & therapeutics, 230, 107964. [CrossRef] [PubMed] [Google Scholar]
- Sommaggio, R., Cappuzzello, E., Dalla Pietà, A., Tosi, A., Palmerini, P., Carpanese, D., Nicolè, L., & Rosato, A. (2020). Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. Oncoimmunology, 9(1), 1777046. [CrossRef] [PubMed] [Google Scholar]
- Yamaga, T., Suehiro, J., Wada, Y., & Sakurai, H. (2022). Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells. Scientific reports, 12(1), 1021. [CrossRef] [PubMed] [Google Scholar]
- Kundur, S., Prayag, A., Selvakumar, P., Nguyen, H., McKee, L., Cruz, C., Srinivasan, A., Shoyele, S., & Lakshmikuttyamma, A. (2019). Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines. Journal of cellular physiology, 234(7), 11103–11118. [CrossRef] [PubMed] [Google Scholar]
- Feng, D., Gao, J., Liu, R., Liu, W., Gao, T., Yang, Y., Zhang, D., Yang, T., Yin, X., Yu, H., Huang, W., & Wang, Y. (2024). CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A. Protein & cell, 15(10), 744–765. [CrossRef] [PubMed] [Google Scholar]
- Kanai Y. (2022). Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacology & therapeutics, 230, 107964. [CrossRef] [PubMed] [Google Scholar]
- Kurozumi, S., Kaira, K., Matsumoto, H., Kurosumi, M., Yokobori, T., Kanai, Y., Sekine, C., Honda, C., Katayama, A., Furuya, M., Shiino, S., Makiguchi, T., Mongan, N. P., Rakha, E. A., Oyama, T., Fujii, T., Shirabe, K., & Horiguchi, J. (2022). Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Scientific reports, 12(1), 2742. [CrossRef] [PubMed] [Google Scholar]
- Okano, N., Hana, K., Naruge, D., Kawai, K., Kobayashi, T., Nagashima, F., Endou, H., & Furuse, J. (2020). Biomarker Analyses in Patients with Advanced Solid Tumors Treated with the LAT1 Inhibitor JPH203. In vivo (Athens, Greece), 34(5), 2595–2606. [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.